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Abstract
Background: Flow cytometric immunophenotyping (FCI), is widely used in cytology for distinguishing between
B-cell lymphoma (BCL) and reactive lymphocytic proliferations (RLP), mainly by identifying monotypic B-cell
populations. Since this cannot always be determined by ratios of surface immunoglobulin light chains (sIg LCs)
we wanted to assess if cytoplasmic immunoglobulin (cIg) LCs, Bcl-2 and polymerase chain reaction (PCR) based
clonality analysis can improve accuracy of cytological diagnoses of BCL.
Methods: Our study included 98 fine needle aspiration biopsies from lymph nodes suspicious for BCL with
inconclusive sIg LCs. In all cases PCR clonality analysis was performed in order to determine immunoglobulin
heavy chain (IGH) gene and T-cell receptor (TRC) gene rearrangement. In selected cases expression of Bcl-2 and
cIg LC were determined by FC.
Results: Thirty patients had lymphoma and 68 had reactive lymphocytic proliferations. Three patterns of sIg LCs
staining were found: negative, dual positive and difficult to interpret. Percentage of lymphomas was highest in
the dual positive group (75 %). Morphology coupled with cIg LCs determination and/or Bcl-2 expression was
able to give a correct diagnosis in 83 % of cases. Molecular tests would have been misleading in 15 % of cases
because 7/30 BCL were polyclonal and 8/68 RLP were monoclonal.
Conclusions: Determination of cIg LCs, Bcl-2 expression and PCR clonality analysis of B cells improved accuracy
of cytological diagnoses in BCL with inconclusive sIg LC. However, clonality determined by PCR was misleading
in some cases.
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Background
Flow cytometric immunophenotyping (FCI), is widely used
in cytology for distinguishing between B-cell lymphoma
(BCL) and reactive lymphocytic proliferations (RLP). A
few lymphoma types can be identified on the basis of an
aberrant immunophenotype. However, differentiation be-
tween BCL and RLP is accomplished mainly by identifying
monotypic populations of B cells [1]. This can be done
reliably by determination of surface immunoglobulin (sIg)
light-chains [2], using mostly the ratio between surface
kappa (κ) and lambda (λ) light chains (LCs) [3–11].
However, in some cases, monotypicity cannot be de-
termined by surface κ/λ ratio, because κ and λ are not
expressed on B cells (negative sIg LCs) or both κ and λ
LC can be detected in the same B cell population (dual
positive sIg LCs). We found few reports mentioning
cases with negative sIg LCs [12–17] and a few articles
reporting cases with dual sIg LCs [17–23]. Some authors
claim that absence of sIg LC is suggestive for B-cell
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lymphoma [12–14]. However, even normal B cells can
down-regulate the expression of sIg LCs, especially in
germinal center B cells and therefore populations with
negative sIg LC can be seen also in RLP [16]. Presence
of dual positive sIg LCs has also been suggested as indi-
cative of BCL [19, 23]. Currently it is still not clear if
dual positive sIg LCs are only a technical problem due
to unspecific staining of Fc receptors [24, 25] or real
biological phenomena [19]. In order to improve cyto-
pathological diagnostics in lymphoproliferative disorders
with inconclusive sIg LC in the absence of specific lymph-
oma immunophenotype cytoplasmic immunoglobulin (cIg)
LCs or Bcl-2 could be helpful. Moreover, molecular studies
especially polymerase chain reaction (PCR) clonality ana-
lysis designed for detection of immunoglobulin heavy chain
gene (IGH) rearrangement, may be essential for the diagno-
sis [26–30]. Authors have reported that high expression of
intracytoplasmic Bcl-2 protein [31–33] and detection of
clonality by determination of cytoplasmic κ/λ ratio [34, 35]
support a lymphoma diagnosis.
In the presented study, we wanted to test if additional
FCI and molecular tests performed on fine needle aspir-
ation (FNA) material could help to distinguish between
BCL and RLP whenever sIg LC determination by FCI
was inconclusive. The aims of the study were: to deter-
mine which inconclusive sIg LC patterns are most often
associated with BCL; to determine if any sIg LC pattern
is associated with a specific histological type of BCL; to
evaluate the diagnostic value of cIg LC and Bcl-2 deter-
mination using FCI; to evaluate the diagnostic value of
IGH and T-cell receptor (TCR) gene rearrangements
studies.
Methods
The study was approved by The National Medical Ethics
Committee of the Republic of Slovenia (109/02/14) and
was performed in compliance with the Helsinki declaration.
Our study included 98 FNA lymph node cases suspi-
cious for primary or secondary BCL in which determin-
ation of sIg LCs by FCI was inconclusive. The second
criterion for inclusion in the study was completion of IGH
and TCR gene rearrangement studies. Our study group
represented 3.3 % of 2938 lymph node cases evaluated by
FCI at the Department of Cytopathology, Institute of On-
cology Ljubljana, Slovenia during the period from March
2006 to March 2012. Determination of sIg LCs was judged
inconclusive when populations of B cells were observed in
the negative or in the dual positive area of the κ and λ dot
plot histograms or when the ratio between κ and λ LCs
could not be reliably determined. The negative or dual
positive populations of B cells were either solitary or
present next to populations of κ and/or λ positive B cells.
In all cases included in the study gene rearrangement
studies of IGH and TCR genes were performed by PCR.
In selected cases, based on the cytopathologist’s decision,
the expression of Bcl-2 and cIg LCs were determined by
FCI. The flow cytometric histograms of Bcl-2 expression
were evaluated by visual approach. The criterion of
Bcl-2 overexpression was that B cells showed greater
Bcl-2 expression than T cells. The Bcl-2 expression
was categorized as not overexpressed when B cells showed
a lower or similar level of Bcl-2 expression as T cells. CIg
LC staining results were conclusive, when they indicated
the presence of a monotypic or polytypic B cell popula-
tion. B cell populations were considered monotypic when
the ratio between κ and λ LCs was larger than 6:1 or lower
than 1:3, and polytypic when the criteria for monotypicyty
was not fulfilled [1].
From patient’s hospital records we obtained clinical
and follow up data as well as cytological and histological
diagnoses for all patients included in the study. Cyto-
logical diagnoses were based on morphological features
of lymphoid cells and FCI results, namely on the aberrant
immunophenotypes and/or on the presence of monotypic
B cell populations. Final diagnoses were based either on
histological results or on cytological results and follow up
data. The cytological diagnosis of lymphoma was consid-
ered correct when it was in accordance with the clinical
course of the disease. The case was considered RLP when
lymphadenopathy resolved itself without treatment. Fol-
low up data were registered from the date of diagnosis
until the end of the study period (January 2015) or until
death of the patient. Statistical analysis of results was per-
formed using descriptive statistics.
Flow cytometric studies
From each FNA lymph node sample two smears were
prepared, one for Giemsa, the other for Papanicolaou
staining. The remaining sample was used for the prepar-
ation of cell suspension. The needle and syringe were
rinsed with 1 ml of cell culture medium (4.5 % bovine
serum albumin, 0.45 % EDTA in phosphate buffer solution
with 90,000 IE/ml of penicillin, and 4 g/ml of garamycin).
The number of cells in suspension was assessed by using
an improved Neubauer cell counting chamber (Brand
GmbH, Wertheim, Germany). Samples for four-color FCI
were prepared according to the protocol adopted for cyto-
logical samples at the Institute of Oncology, Ljubljana,
Slovenia [36]. The samples were first filtered through
50 μm pore filter (CellTrics, Partec GmbH, Germany). In
cases of low cellularity we used whole sample. Otherwise
200,000 cells, and 1.5 ml buffer (Cell Wash –BD Biosci-
ences) were put in each test tube, mixed and centrifuged
at 1500 rpm for 5 min (Hettich, Universal 32 centrifuge,
Germany). The supernatant was discarded and appro-
priate amounts (3 or 5 μl) of antibodies were added as
predetermined by titration. We used monoclonal anti-
bodies against CD45, CD19, CD20, CD3, CD10, CD5,
Brozic et al. Diagnostic Pathology  (2015) 10:191 Page 2 of 10
CD23, FMC7, κ and λ LCs (BD Biosciences). The samples
were then mixed and incubated in darkness for 20 min.
After incubation, 1.5 ml of buffer (Cell Wash – BD Biosci-
ences) was added to the sample, mixed and centrifuged at
1500 rpm for 5 min (Hettich, Universal 32 centrifuge,
Germany). The supernatant was discarded and 300 μl of
buffer (Cell Wash – BD Biosciences) was added.
For the determination of Bcl-2 and cIg LCs, samples
were fixed and permeabilized with Fix & Perm cell
permeabilization kit, according to the manufacturer’s
recommendations (Invitrogen, USA). Three-color com-
bination of 6 or 10 μl of antibodies was used for Bcl-2
staining (Bcl-2; DAKO, Denmark, CD19, CD45; BD
Biosciences,) and four-color combination of antibodies
for cIg LCs (κ, λ, CD19, CD10; BD Biosciences,). We ran
isotype controls (BD Biosciences) with each analysis.
The samples were acquired using four-color flow cyt-
ometer FACSCalibur (BD Biosciences) or six-color flow
cytometer FACSCanto II (BD Biosciences). During sample
acquisition at least 20,000 CD19 positive events were col-
lected. For low cellularity samples all CD19 positive events
were collected. The measurement results were analyzed
using CellQuest (BD Biosciences) or BD FACSDiva soft-
ware (BD Biosciences). For result analysis combined side
scatter (SSC) and surface marker (CD19) gating was used.
IGH and TCR gene rearrangement studies
PCR clonality analysis of lymphoid cells was used to
study IGH and TCR gene rearrangement. Genomic
DNA from FNA samples was isolated using HighPure
PCR Template Preparation Kit (Roche Applied Science,
Penzberg, Gremany) according to the method recom-
mended by the manufacturer. The amount and the purity
of the extracted DNA were assessed by using spectropho-
tometer at A260nm/A280nm (NanoDrop, ThermoScientific,
Wilmington, USA). Clonality analysis was performed
using in-house and BIOMED-2 clonality assays – ABI
Fluorescence Detection (Identiclone; InVivo Scribe
Technologies, San Diego, CA, USA). For 32 cases analyzed
before the implementation of BIOMED-2 method, in-
house method was used. In this method two consensus
oligonucleotide primers against VH-FR3 and JH region
were used for amplifications of IGH rearrangements.
Two primer sets including nine consensus primers
were used to amplify the Vγ and Jγ gene segments of
TCR-γ locus [37]. Clonality assessment was performed
by using BIOMED-2 clonality assay according to the
instructions of the manufacturer and as previously de-
scribed [28]. The products were size-fractionated using
polyacrylamide gel electrophoresis or capillary gel elec-
trophoresis on an ABI 3500 genetic analyzer (Applied
Biosystems, Foster City, CA, USA) and analyzed by
fragment analysis (GeneScan).
Results
Clinical data and pathological findings
The 98 FNA cases included in the study were obtained
from 98 patients, 61 females and 37 males. The age of
the patients ranged from 4 to 94 years (average 49 years).
Follow up ranged from 35 to 104 months (average
66 months). Based on the final diagnoses our study group
included 30 patients with BCL and 68 patients with RLP
(Table 1). In 83 % of cases cytopathological diagnosis was
concordant with histology and/or follow up. There were 9
correctly suspicious diagnoses, six incorrectly suspicious,
one false negative and one false positive diagnosis.
Histological examination was performed in 40 patients,
25 (63 %) patients had BCL, 14 (35 %) had RLP, and one
(2 %) biopsy was not representative. Histologically con-
firmed BCL included nine diffuse large B-cell lymphomas
(DLBCL), six marginal zone lymphomas (MZL), 7 follicu-
lar lymphomas (FL), 2 B-cell lymphomas not otherwise
specified, and 1 composite MZL and T-cell lymphoma. In
the patient with non- representative biopsy the final diag-
nosis was DLBCL, confirmed by cytology and follow-up
data (Table 1).
Cytological diagnoses were consistent with histology in
26/40 cases (65 %): in 15/25 lymphomas and in 11/14
RLP. There were nine correct suspicious cytological diag-
noses, three incorrect suspicious and 1 false negative.
In 58 patients only cytological examination was per-
formed. We diagnosed 50 reactive lymphocytic prolifera-
tions and five lymphomas: two MZL, 1 DLBCL, 2 B-cell
lymphomas not otherwise specified. Three cases were
signed out as suspicious for lymphoma. Cytological diagno-
ses of all 50 RLP and 4/5 lymphomas were concordant with
follow up data. However, lymphoma was not confirmed in
all three patients with suspicious cytological diagnosis
of lymphoma and neither in one patient with positive
cytological diagnosis.
Flow cytometric findings
According to the patterns of sIg LCs determined by FCI we
divided cases into three main groups, negative (Fig. 1a, b),
dual positive (Fig.1c, d), and difficult to interpret (Fig.1e, f).
SIg LCs were negative in 63/98 (64 %) cases and dual
positive in 20/98 (20 %) cases. The percentages of cells
with negative and dual positive sIg LCs ranged from 24
to 88 % (median = 52) and 15 to 100 % (median = 80), re-
spectively. In all cases with negative sIg LCs we observed
additional cell populations either polytypic (36/63) or
monotypic (27/63) (Fig. 1a, b). Five of cases with add-
itional monotypic populations and five of those with
polytypic populations were BCL. In cases with dual
positive sIg LCs 14 cases had only the population of
dual positive sIg LCs (Fig. 1c) and six cases also had
polytypic populations (Fig. 1d). Four/6 cases with additional
polytypic populations were BCL.
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Table 1 Correlation between cytological and final diagnoses
Cytological diagnoses
Final diagnoses DLBCL FL MZL BCL-NOS Suspicious for lymphoma RLP
DLBCL (11) 7 - - - 4 -
FL (7) - 5 - 2 - -
MZL (10) - - 4a 1 4 1
BCL-NOS (2) 1 - - - 1 -
RLP (68) - - - 1 6 61
TOTAL (98) 8 5 4 4 15 62
BCL B-cell lymphoma, DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma, MZL marginal zone lymphoma, NOS not otherwise specified, RLP reactive
lymphocytic proliferations
aOne case composite lymphoma: marginal zone and T-cell lymphoma
Fig. 1 Flow cytometric dot plots showing patterns of sIg LCs. Negative (a,b), dual positive (c,d), and difficult to interpret (e,f)
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In 15 (15 %) cases sIg LCs were difficult to interpret
because of unusual patterns or because too few CD19
positive cells were acquired.
Figure 2 shows the percentage of BCL within the three
groups. The percentage of BCL was highest in the dual
positive group (75 %; 15/20) as compared to the negative
(16 %; 10/63), and the difficult to interpret group (33 %;
5/15).
DLBCL, FL and MZL were found among all the incon-
clusive patterns of sIg LCs without a clear predominance
of any lymphoma type within a particular group (Table 2).
Five/7 FL were of high grade, two in the negative and
three in the dual positive group.
Results of cIg LC determination were available in 29/
98 cases with inconclusive sIg LCs: for 19 (30 %) cases
in the negative group, for 10 (50 %) cases in the dual
positive group and none in the difficult to interpret
group. Eighteen cases from the negative sIg LC group
were negative also for cIg LCs and one was polytypic
(Table 3). Follow-up data showed that all these cases
were from RLP. However, in the dual positive sIg LC
group cIg LCs were monotypic in 8/10 (80 %) cases.
Seven/8 monotypic cases were from lymphomas and
one case was from a patient with spontaneous regres-
sion of lymph nodes. Of the remaining two cases from
the dual positive sIg LC pattern one had dual cIg LCs
while the second had negative cIg LCs (Table 3). The
case with dual positive LCs was lymphoma and the case
with negative LCs was RLP.
Bcl-2 results were available for 34/98 cases of our
study group, 13/30 cases of lymphomas and 21/68 cases
of RLP. Bcl-2 overexpression was present in 8/13 lymph-
omas. None of the RLP showed Bcl-2 overexpression.
Expression of Bcl-2 in lymphomas and reactive lymph
nodes within different sIg LC patterns is shown in Table 3.
IGH gene and TCR gene rearrangement studies
IGH gene rearrangement results were available for all 98
cases of our study. 32/98 (33 %) cases were monoclonal
and 66/98 (67 %) were polyclonal. Monoclonal B cells
were found in 23/30 (77 %) cases with final diagnosis of
BCL and in 8/68 (12 %) RLP. In addition, TCR gene re-
arrangement studies showed that 12/98 (12 %) cases had
also monoclonal T-cell populations in both BCL (3/30;
10 %) and in RLP (9/68; 13 %) (Table 4). One of lymph-
omas with monoclonal T cells was composite MZL and
T-cell lymphoma. The results of IGH and TCR gene re-
arrangement studies for cases in negative, dual positive
and difficult to interpret sIg LC staining groups are pre-
sented in Table 4. Differences in the percentages of
lymphoma and RLP in which IGH gene rearrangement
studies detected monoclonal B cell populations are
shown in Fig. 3.
Discussion
This study showed that additional FCI tests performed
on FNA samples from lymph nodes helped to distin-
guish between BCL and RLP in cases with inconclusive
sIg LC determination by FCI. Morphology coupled with
cIg LC determination and/or Bcl-2 expression was able
to give a correct diagnosis in 83 % of cases. Molecular
tests, which were not included in the decision on the
Fig. 2 Percentage of lymphomas in each group of sIg LCs. Cases with specific patterns of sIg LCs determined by FCI (blue columns, left axis) and
the percentage of lymphomas within these three groups (red dots, right axis)
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original cytological diagnoses, could have contributed
positively in 85 % and would have been misleading in
15 % of cases.
Accuracy of cytopathologic diagnoses
The results of our study are similar to those reported by
Laane et al.[33]. They were able to correctly classify
89 % of their cases which is slightly better than our re-
sult. However, their study was not selective and did not
include only problematic cases with inconclusive sIg
LCs. In addition to the 83 % correct diagnoses. The one
case which we labeled as the false positive cytological re-
sult was morphologically a lymphoma which regressed
completely without therapy. In addition to the small B
cell population with dual sIg LCs there was a monotypic
population of large B cells with positive surface and
cytoplasmic κ LCs, expressing CD5 and lacking CD10. It
is doubtful whether this was a true false positive result
because spontaneous regression of non-Hodgkin lymph-
oma has been reported previously. Krikorian et al.[38]
have reported seven cases of lymphoma with favorable
histologic subtypes which regressed without treatment.
Iwatani et al. [39] reported a case of an aggressive high
grade lymphoma of the breast which regressed after core
biopsy.
Patterns of inconclusive sIg LCs
Our FCI findings showed three main groups of inconclusive
sIg LCs patterns in lymphomas and in RLP (Fig. 1). No
specific lymphoma type was associated with a particular
sIg LC pattern. The dual positive sIg LC pattern showed
the highest risk for BCL, since 75 % of cases in this group
were lymphomas. The presence of dual positive sIg LCs
has been previously reported as case reports, mostly in
chronic lymphatic leukemia (CLL) [18, 20, 22, 23] as well
as individual cases of MALT lymphomas [40, 41]. Only
one report describes an aggressive large cell lymphoma,
histologically undetermined [19]. In contrast to the major-
ity of indolent lymphomas reported in the literature our
group of 15 lymphomas with dual sIg LCs included 5 ag-
gressive DLBCL. It has been suggested that dual positive
sIg LC pattern may be the result of unspecific staining
which could be minimized by more extensive washing of
the sample or by prolonged incubation in isotonic buffer
[24]. However, according to our experience such proce-
dures result in some cell loss which may hinder FCI deter-
minations in samples which are not highly cellular.
Only 16 % of cases in the negative sIg LC group of our
study were BCL. Therefore we concluded that this pattern
of LC expression has a low risk for lymphoma. These
results are in contrast with the results of some authors
who claim that negative sIg LCs can be used as a sub-
stitute of monotypicyty because such cases are found
mostly among lymphomas [12, 13]. Zhao [16] warned
that benign follicular hyperplasia can also have negative
sIg LC pattern. However, he found only three such
cases among 101 reactive lymphadenopathies. Further-
more, frequency of lymphomas with negative sIg LCs
reported in the literature depends on the criteria used
and ranged from 3.4 to 12.2 % as stated by Li et al.[13].
His criterion was complete lack of sIg LCs and the fre-
quency of such lymphomas was 2.3 %. In the study by
deMartini et al. [17] the criterion was less than 15 % κ
positive and less than 10 % λ positive cells and therefore
Table 2 Types of lymphomas detected in negative, dual
positive and difficult to interpret groups
Type of lymphoma Negative Dual positive Difficult to interpret Total
DLBCL 3 5 3 11
FL 3 3 1 7
MZL 3 6a 1 10
BCL, NOS 1 1 0 2
Total 10 15 5 30
BCL B-cell lymphoma, DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma,
MZL marginal zone lymphoma, NOS not otherwise specified
aOne case composite lymphoma: MZL and T-cell lymphoma
Table 3 CIg LCs and Bcl-2 expression in groups with negative and dual positive sIg LCs patterns
sIg LCs
cIg LCs Negative (n = 19) Dual positive (n = 10) Total (n = 29)
Monotypic 0 8 8
Polytypic 1 0 1
Negative 18 1 19
Dual positive 0 1 1
Bcl-2 Diagnosis Negative (n = 25) Dual positive (n = 9) Total (n = 34)
Overexpressed BCL 2a 6b 8
Not overexpressed BCL 4 1 5
RLP 19 2 21
BCL B-cell lymphomas, RLP reactive lymphocytic proliferations, sIg LCs surface immunoglobulin light chains, cIg LC cytoplasmic immunoglobulin light chains;
a2 FL; b2 DLBCL, 2 FL, 2 MZL
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the percentage of sIg LC negative lymphomas was 13 %.
One of the reasons for low percentage of lymphomas with
negative sIg LCs in our study is absence of CLL and
mantle cell lymphoma. In our daily practice we did en-
counter occasional cases of these two lymphomas which
lacked sIg LCs. However, such cases expressed a typical
immunophenotypes for CLL and therefore additional FCI
or molecular investigations were not performed.
We have found no reports on lymphadenopathies ex-
pressing sIg LCs that are difficult to interpret. It seems
that such cases are usually excluded from studies [13].
Since the majority of such cases in our study had low
cellularity we were not able to do additional FCI analysis.
Determination of cIg LCs
Investigation of cIg LCs is also not reported frequently.
We have found only one report which described cIg LCs
in a series of lymphomas [34]. Lewis et al. [34] studied
30 cases of CLL because week expression of sIg LCs is
one of the five criteria in the international scoring sys-
tem to help discriminate between CLL and other BCL.
They found that 6/7 cases with negative sIg LCs had
positive cIg LCs. This result has been commented by
Smith et al. [14] in their report on a case of FL which
lacked both sIg and cIg LCs. Smith et al. [14] speculated
that the results of Lewis et al. [34] suggested that investi-
gating both types of light chains would significantly in-
crease the chance of detecting LC restriction. Since the
study only included CLL it was not clear whether such
conclusion was applicable to other types of lymphomas.
Even though we were able to investigate the presence of
cIg LCs only in 30 % of cases, our results do shed some
light on the usefulness of such testing. We were able to
detect cIg LC restriction in 8/9 lymphomas where sIg
LCs had dual positivity. In the group of cases with nega-
tive sIg LCs 18/19 cases also lacked cIg LCs and one
case was polyclonal. All these 19 cases were from RLP.
Unfortunately our study does not include any lymphoma
Table 4 Monoclonal gene rearrangement results in negative, dual positive, and difficult to interpret surface light chains staining
group
sIg LCs staining groups
Gene rearrangement Final diagnosis Negative (N1/N) Dual positive (N1/N) Difficult to interpret (N1/N) Total (N1/N)
monoclonal B cells B-cell lymphoma 7/10 13/15 3/5 23/30
Reactive 5/53 2/5 1/10 8/68
total 12/63 15/20 4/15 30/98
monoclonal T cells B-cell lymphoma 1/10 2/15a 0/5 3/30
reactive 9/53 0/5 0/10 9/68
total 10/63 2/20 0/15 12/98
N1 lymphoma cases, N all cases in the group, sIg LCs surface immunoglobulin light chains, BCL B-cell lymphomas, RLP reactive lymphocytic proliferations
aCase of composite MZL and T-cell lymphoma
Fig. 3 Results of IGH gene rearrangement studies in three different sIg LC patterns. The red columns represent the proportion of cases with
monoclonal B cells in BCL. The blue columns represent the proportion of cases with monoclonal B cells in RLP. Final diagnoses are considered
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with negative sIg LCs in which cIg LCs were determined.
However, we have a few lymphoma cases in our files
with negative sIg LCs and negative cIg LCs (unpublished
data). Absence of sIg and cIg LCs is rare in lymphomas.
In addition to CLL and FLs mentioned above, the lack
of cIg LCs has also been reported in two Burkitt lymph-
omas [42].
Bcl-2 expression
Bcl-2 expression is mainly used as an ancillary method
in the differentiation between FL and benign follicular
hyperplasia. The presence of overexpression of Bcl-2 in
other lymphoma types is not well documented. Our
results are concordant with data from the literature
[31, 32] that Bcl-2 is overexpressed in approximately
85 % of FL and not overexpressed in reactive lymph
nodes (Table 3). However, Laane et al. [33] found two
cases among 137 reactive hyperplasias in which a sub-
population of B cells expressed high levels of Bcl-2.
The study was performed on FNA material and these
two cases were signed out as suspicious for lymphoma.
Our study of Bcl-2 expression included eight cases of
lymphoma other than FL and overexpression was ob-
served in half of them (Table 3). The number of individual
lymphoma types investigated for Bcl-2 overexpression in
our study and in the report of Cook et al. [31] is too low
to draw any important conclusions. Laane et al. [33] on
the other hand, investigated 117 non-FL for Bcl-2 expres-
sion. They found high levels of Bcl-2 expression in all 88
indolent lymphomas, however, these expressions were
lower than in FLs. Among the 29 aggressive lymphomas
of their study, high levels of Bcl-2 expression were present
only in nine cases which were CD10 positive.
The main weakness of our study was the fact that cIg
LC determination and Bcl-2 expression were performed
only in 30 and 35 % of cases respectively. Furthermore,
presence of cIg LCs was not performed in any lymph-
omas with negative sIg LCs. The reason for this draw-
back is the criterion for inclusion of cases in our study
which required that all cases with inconclusive sIg LC
also have results of IGH and TCR gene rearrangement
studies. In this way we lost some cases with inconclusive
sIg LCs in which cIg LCs and/or Bcl-2 expression were
performed. This is also the reason for the absence of CLL
and mantle cell lymphomas from our study as well as the
absence of lymphomas with negative sIg and cIg LCs.
Molecular tests
The outcome of our molecular tests was somewhat dis-
appointing since they were concordant with final diag-
noses in 85 % and misleading in 15 % of our cases. They
showed monoclonality in only 77 % of BCL. We were
unable to detect monoclonality in 3 DLBCL, 3 FL, and 1
MZL. On the other hand, monoclonality of B cells was
present also in 12 % of RLP, while monoclonal popula-
tions of T cells were present in 12 % of all our cases.
With the use of molecular test our detection rate of
BCL was lower than reported by EuroClonality/BIOMED-
2 group where clonal IGH-gene rearrangement was found
in 91 % of BCL [29]. The frequency of monoclonal B cell
populations in RLP was similar to the reported 10 % of the
EuroClonality/BIOMED-2 group. There are several rea-
sons for under-detection of BCL by the PCR technique
such as suboptimal sampling, few lymphoma cells in react-
ive background, the use of imperfect consensus primers,
atypical rearrangement or somatic hypermutation [43, 44].
The somatic hypermutation is most common among
malignant lymphomas that arise from B cells exposed to
antigen, such as FL and DLBCL or MZL [44] and was
most probably the main cause for under-detection of
monoclonality in our study. The second reason was prob-
ably the use of less sensitive in-house PCR clonality ana-
lysis in one third of our cases. To enhance the sensitivity
of PCR clonality analysis of B cells, immunoglobulin kappa
light chain gene rearrangement studies are advisable [45].
PCR based IGH and TCR gene rearrangement studies
are not frequently used in routine cytological diagnostics
of BCL because FCI has been proven as a sensitive and
specific ancillary technic for differentiation between BCL
and RLP [1, 46]. However, FCI may not be helpful in
cases of low cellularity, whenever there are few lymph-
oma cells in a reactive background or when FCI results
are inconclusive. Safley et al. [47] therefore proposed a
combined diagnostic algorithm including microscopic
analysis, FCI and molecular evaluation for the diagnosis of
BCL by FNA. According to this algorithm PCR clonality
analysis of lymphoid cells and detection of specific translo-
cations by FISH should be reserved only for cases in which
FCI fails to detect a monotypic B cell population [47]. Ri-
bera et al. [48] have recently used a similar approach in
102/722 (14 %) cases of lymphoproliferative disorders with
inconclusive FCI results. In their series PCR based IGH
clonality analysis implied malignancy, because all mono-
clonal cases were BCL. However, 26.3 % (5/19) of BCL
were missed because PCR results were polyclonal, 26.3 %
(5/19) were missed because PCR result were inconclusive
or not informative. Despite of that the authors concluded
that PCR clonality analysis of lymphoid cells could be
helpful if the results are interpreted along with clinical and
morphological findings [48]. Our results on PCR based
IGH and TCR gene rearrangement studies are in con-
cordance with the results published by Safley et al. [47]
and Ribera et al. [48].
Conclusion
In our study determination of cIg LCs, Bcl-2 expression
and PCR clonality analysis improved accuracy of cyto-
logical diagnoses in BCL with inconclusive sIg LCs. Dual
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positive sIg LCs were more frequent in BCL than in RLP
and determination of cIg LCs showed monotypic popu-
lations in most cases. Therefore, we propose that cIg LC
should be determined first in such cases since determin-
ation of Bcl-2 expression might not be necessary. On the
other hand, our results showed that the majority of RLP
and lymphomas with negative sIg LCs also had negative
cIg LCs . Therefore, we propose that Bcl-2 expression
should be a priority in such cases. However, lack of cIg
LCs and lack of Bcl-2 overexpression do not rule out
lymphoma. When cIg LCs and Bcl-2 are not helpful
PCR clonality analysis should be performed. Monoclonal
result implies lymphoma but is not an absolute proof
and polyclonal result does not rule out lymphoma.
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